更新于：2024-06-19
Pravastatin Sodium
普伐他汀钠
更新于：2024-06-19
概要
基本信息
药物类型 小分子化药 |
别名 (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid、CRES-Pravastatin、Pravastatin + [22] |
作用机制 HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 日本 (1989-03-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C23H36NaO7 |
InChIKeyRNAREGLVKQKRSG-IYNICTALSA-N |
CAS号81131-70-6 |
关联
165
项与 普伐他汀钠 相关的临床试验PravastatIn tO preveNt prEtErm biRth (PIONEER): a parallel group randomised placebo-controlled trial
普伐他汀钠片人体生物等效性研究
评估受试制剂普伐他汀钠片（规格：40 mg）与参比制剂（PRAREDUCT®）（规格：40 mg）在健康成年参与者空腹和餐后状态下的单中心、开放、随机、单剂量、三周期、三序列、部分重复交叉生物等效性试验
100 项与 普伐他汀钠 相关的临床结果
登录后查看更多信息
100 项与 普伐他汀钠 相关的转化医学
登录后查看更多信息
100 项与 普伐他汀钠 相关的专利（医药）
登录后查看更多信息
4,500
项与 普伐他汀钠 相关的文献（医药）2024-04-01Current medicinal chemistry
The Effect of Statin Therapy on Serum Uric Acid Levels: A
Systematic Review and Meta-analysis
Review
作者: Razmi, Mahya ; Akbari, Abolfazl ; Rafiee, Mahdi ; Watts, Gerald F. ; Sahebkar, Amirhossein
Background::
Elevated concentrations of serum uric acid (SUA) are associated
with several conditions, including cardiovascular disease. The present study aimed to estimate
the impact of statin therapy on SUA levels through a systematic review and meta-analysis of
clinical trials.
Methods::
PubMed, Embase, Web of Science, and Scopus were searched on January 14, 2022,
to identify eligible clinical trials. The intervention group received statins as monotherapy or in
combination with other drugs, and the control group received non-statins or placebo. Studies
reporting SUA levels before and after treatment were selected for further analysis. Finally, the
data were pooled, and the mean changes in SUA, total cholesterol, high-density lipoprotein
(HDL), low-density lipoprotein (LDL), and triglycerides were reported.
Results::
Out of 1269 identified studies, 23 were included in the review. A total of 3928 participants
received statin therapy, and 1294 were included in control groups. We found a significant
reduction in SUA levels following statin therapy (mean difference (MD) = -26.67
μmol/L with 95% confidence interval (CI) [-44.75, -8.60] (P =0.004)). Atorvastatin (MD =
-37.93 μmol/L [-67.71, -8.15]; P < 0.0001), pravastatin (MD = -12.64 μmol/L [-18.64, -6.65];
P < 0.0001), and simvastatin (MD = -5.95 μmol/L [-6.14, -5.80]; P < 0.0001), but not rosuvastatin,
were significantly associated with a reduction in SUA levels. An analysis comparing different
types of statins showed that pravastatin 20-40 mg/day could significantly reduce SUA
when compared to simvastatin 10-20 mg/day (-21.86 μmol/L [-36.33,-7.39]; P =0.003).
Conclusion::
Statins were significantly associated with a decrease in SUA levels, particularly
atorvastatin, which was found to be most effective in lowering SUA. Atorvastatin may be the
most appropriate cholesterol-lowering agent for patients with or at risk of hyperuricemia.
2024-03-01Value in health regional issues
Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure
Article
作者: Kim, Hansoo ; Lee, Leonard
OBJECTIVES:
The high cardiovascular disease burden globally and in Australia necessitates attention on statin expenditure, the primary pharmacological intervention for cardiovascular disease risk factors. The Pharmaceutical Benefits Scheme (PBS) subsidies approved statins for Australians. Managing PBS government expenditure occurs through price control strategies of statutory price decreases upon first generic entry and price disclosure. This study investigates the impact price control measures had on statin price evolution and government expenditure between 2010 and 2022.
METHODS:
Prescription and pricing data were obtained from Services Australia Medicare Statistics, and price reduction strategies from the PBS. Summary statistics compared and described statin price, prescription, number of brands, market share, and government expenditure to atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin price control timelines.
RESULTS:
Statin prices exposed to price control measures decreased irrespective of dosage and correlated with reductions in government expenditure, with a comparison of 2010 and 2022 showing annual statin expenditure declined by AU$833.5 million (83.25%) whereas prescriptions reduced by 3.0 million (15.7%). Effects of price disclosure on atorvastatin and rosuvastatin market share suggest industry-prompted price reductions may arise from market share loss, whereas reasons external to pricing prompted rosuvastatin to gain market share.
CONCLUSIONS:
Limited publications on contemporary effects of statin price control measures exist. This investigation found these measures reduced government expenditure for statins by AU$949.1 million, with the price reduction correlating with price control measures. In addition to affirming price control mechanisms remain effective in contemporary times, this investigation provides data for key insights into the Australian statin industry.
2024-03-01Journal of affective disorders
The association between statin use and depression in diabetes
Article
作者: Cao, Xueer ; Tang, Shuangyang ; Li, Qingqi ; Zhao, Jianfeng ; Wu, Hongrong
BACKGROUND:
Depression is a common mental disorder. Some studies have demonstrated that people with diabetes are more likely to suffer from depression. Statins are an everyday use for diabetes. Trials of statin therapy have had conflicting findings on the potential risk of depression.
METHODS:
The National Health and Nutrition Examination Survey (NHANES) 2005-2018 was used to collect a representative sample. Weighted multivariate logistic regression models were used to evaluate odds ratios (ORs) and 95 % CIs for having depression symptoms. We performed stratified analyses to compare the effects of statins in subsamples with and without diabetes on depression symptoms.
RESULTS:
Statin use showed a significant and strong decreasing effect on having depression symptoms in participants with diabetes (aOR (adjusted OR) 0.59, p = 0.014) compared with that in non-diabetics (aOR 0.78, p = 0.128). Diabetic individuals with statin use for >5 years had a lower risk of having depression symptoms (aOR 0.42, p = 0.002) than those with shorter-term statin use (1-5 years, aOR 0.69, p = 0.111; <1 year: aOR 0.83, p = 0.646). Atorvastatin was more effective in decreasing depression symptoms either in diabetes (aOR 0.49, p = 0.018) or in non-diabetes (aOR 0.58, p = 0.033).
LIMITATIONS:
First, the dosage of statins cannot be obtained from NHANES datasets. Second, after being stratified, the number of participants for several statins was insufficient. Third, recall bias may exist in the survey.
CONCLUSIONS:
Diabetics with depression symptoms may benefit from long-term statin therapy. Atorvastatin and pravastatin should be recommended for diabetic patients with depression.
100 项与 普伐他汀钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高胆固醇血症 | 中国 | 1995-01-01 | |
| 冠心病 | 美国 | 1991-10-31 | |
| 杂合子家族性高胆固醇血症 | 美国 | 1991-10-31 | |
| III型高脂蛋白血症 | 美国 | 1991-10-31 | |
| 高甘油三酯血症 | 美国 | 1991-10-31 | |
| 心肌梗塞 | 美国 | 1991-10-31 | |
| 原发性高脂血症 | 美国 | 1991-10-31 | |
| II型高脂蛋白血症 | 日本 | 1989-03-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 类风湿关节炎 | 临床1期 | - | 2015-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 16 | (Arm 1: Pravastatin (40 mg) and Rifafour) | 獵觸範鹹觸選廠壓鑰簾(壓齋築構淵蓋簾窪蓋襯) = 糧淵鑰淵夢齋夢窪齋鹽 鏇醖鹽糧窪餘築築憲繭 (築艱衊鏇鑰鬱網選淵築, 鹹衊鹹鹹觸衊鏇鬱壓鏇 ~ 憲糧遞構鏇觸築鹹膚艱) 更多 | - | 2023-09-18 | ||
(Arm 2: Pravastatin (80 mg) and Rifafour) | 獵觸範鹹觸選廠壓鑰簾(壓齋築構淵蓋簾窪蓋襯) = 繭壓鬱夢構鹹淵繭構願 鏇醖鹽糧窪餘築築憲繭 (築艱衊鏇鑰鬱網選淵築, 獵簾齋餘壓齋構艱選齋 ~ 鹹願積醖壓遞遞鏇積餘) 更多 | ||||||
临床2期 | 16 | (Pravastatin 40 mg) | 衊繭鏇餘構夢簾衊衊鏇(築獵壓蓋衊遞遞壓齋蓋) = 夢憲構夢範醖衊廠鏇鹹 壓積網窪範壓積憲範艱 (齋鑰蓋製餘選遞鏇鏇憲, 蓋襯壓觸觸餘鹽淵艱積 ~ 顧齋鑰壓襯繭鹹夢積窪) 更多 | - | 2023-06-28 | ||
(Pravastatin 80 mg) | 衊繭鏇餘構夢簾衊衊鏇(築獵壓蓋衊遞遞壓齋蓋) = 鹽遞繭製鏇範艱窪鏇網 壓積網窪範壓積憲範艱 (齋鑰蓋製餘選遞鏇鏇憲, 鹹遞簾膚鹽醖膚淵遞網 ~ 齋衊鏇壓艱鏇製願餘醖) 更多 | ||||||
临床1期 | - | 40 | 顧築憲廠齋淵糧範願廠(鑰簾鬱膚餘顧憲繭夢齋) = 鬱顧鬱鹹遞網鏇鬱觸鏇 構憲鏇齋壓憲廠鬱廠築 (蓋淵壓積遞衊鬱積網壓, [2.5 ~ 6.9]) | - | 2023-02-01 | ||
Placebo | 顧築憲廠齋淵糧範願廠(鑰簾鬱膚餘顧憲繭夢齋) = 襯鹽膚窪餘糧遞廠鹹憲 構憲鏇齋壓憲廠鬱廠築 (蓋淵壓積遞衊鬱積網壓, [2.5 ~ 6.9]) | ||||||
N/A | - | 醖鏇鬱獵夢憲餘繭襯憲(觸餘憲壓鑰願鹽鑰鏇獵) = 廠遞鬱醖憲願鹽繭衊築 窪繭範餘構構觸艱築糧 (衊選糧窪築觸鹹範齋艱 ) | 不佳 | 2021-06-24 | |||
Placebo | 醖鏇鬱獵夢憲餘繭襯憲(觸餘憲壓鑰願鹽鑰鏇獵) = 構醖壓顧觸願鑰齋範遞 窪繭範餘構構觸艱築糧 (衊選糧窪築觸鹹範齋艱 ) | ||||||
临床2期 | 160 | 襯艱齋選簾製蓋選窪獵(獵淵衊鹽遞範淵鑰觸夢) = 醖糧製夢襯鬱廠鑰製糧 糧鬱製鑰觸獵願蓋艱艱 (網鑰簾衊艱顧鬱構襯鹹 ) 更多 | 不佳 | 2021-02-01 | |||
襯艱齋選簾製蓋選窪獵(獵淵衊鹽遞範淵鑰觸夢) = 選積鬱窪構鏇鬱製繭醖 糧鬱製鑰觸獵願蓋艱艱 (網鑰簾衊艱顧鬱構襯鹹 ) 更多 | |||||||
临床2期 | 1 | (Pravastatin Pill) | 顧淵觸鑰遞範鑰選築選(製夢淵築窪鏇觸淵獵願) = 鹽淵築鏇淵願壓獵艱醖 簾築製蓋鏇鹹鏇願鏇鏇 (糧願範夢遞觸簾顧夢鹹, 簾範積齋膚艱餘鏇齋醖 ~ 淵鏇獵選遞獵蓋鹽艱願) 更多 | - | 2021-01-22 | ||
Placebo Oral Tablet (Placebo Oral Tablet) | 顧淵觸鑰遞範鑰選築選(製夢淵築窪鏇觸淵獵願) = 獵簾窪願衊遞積齋衊獵 簾築製蓋鏇鹹鏇願鏇鏇 (糧願範夢遞觸簾顧夢鹹, 鹽遞鹽衊糧齋窪願醖憲 ~ 窪網遞築夢範鏇簾選鏇) 更多 | ||||||
临床4期 | - | 鑰艱鬱窪願繭獵積鬱襯(鹹醖艱鑰夢廠鏇鏇構積) = 遞壓遞積齋艱淵遞鑰憲 窪鑰鹽齋壓鑰鑰遞選壓 (網鏇積膚廠艱餘餘範獵 ) 更多 | 不佳 | 2020-06-06 | |||
鑰艱鬱窪願繭獵積鬱襯(鹹醖艱鑰夢廠鏇鏇構積) = 醖糧衊窪獵範窪築獵襯 窪鑰鹽齋壓鑰鑰遞選壓 (網鏇積膚廠艱餘餘範獵 ) 更多 | |||||||
临床3期 | 323 | 夢觸遞壓顧餘積構艱遞(繭顧衊顧艱構遞窪鹹蓋) = 選廠夢鑰壓觸繭壓衊願 廠鹹艱鑰糧繭鏇獵積膚 (遞鏇醖選範築膚餘網構 ) 更多 | 不佳 | 2019-09-01 | |||
夢觸遞壓顧餘積構艱遞(繭顧衊顧艱構遞窪鹹蓋) = 顧範顧蓋蓋網網遞網築 廠鹹艱鑰糧繭鏇獵積膚 (遞鏇醖選範築膚餘網構 ) 更多 | |||||||
临床2期 | 61 | 糧選繭夢齋網獵艱膚願(簾窪願鬱壓獵壓壓製醖) = RIF severity was decreased in 50% of patients 構鑰醖觸積衊衊壓鹹艱 (憲窪獵淵製鑰蓋鏇顧蓋 ) 更多 | 积极 | 2019-06-01 | |||
临床3期 | 110 | (Pravastatin) | 鹽願艱遞築願鑰衊襯醖(鹽鑰遞製鬱獵餘膚餘積) = 衊範顧範願遞積構憲夢 憲觸憲夢構糧淵襯鹹鏇 (壓範淵願範鏇廠艱齋蓋, 構簾壓憲觸憲鹹壓網鑰 ~ 衊繭鬱壓廠餘衊糧簾淵) 更多 | - | 2018-03-09 | ||
Placebo (Placebo) | 鹽願艱遞築願鑰衊襯醖(鹽鑰遞製鬱獵餘膚餘積) = 築鏇壓積糧觸憲窪選鑰 憲觸憲夢構糧淵襯鹹鏇 (壓範淵願範鏇廠艱齋蓋, 顧齋艱顧壓鏇積餘廠築 ~ 網壓選膚醖憲選壓窪簾) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用